Therapeutic Asset Ratings

250 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
FILGRASTIM Hepatocellular Carcinoma	Mayo Clinic	P2	CCC (52)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER Hepatocellular Carcinoma	Virginia Commonwealth University	P2	CCC (52)
Liocyx-M Hepatocellular Carcinoma	Lion TCR Pte. Ltd.	P2	CCC (52)
Neoantigen Dendritic Cell Vaccine Hepatocellular Carcinoma	National Cancer Centre, Singapore	P2	CCC (52)
NWRD06 Hepatocellular Carcinoma	Newish Technology (Beijing) Co., Ltd.	P2	CCC (52)
Sonidegib Hepatocellular Carcinoma	University of Florida	P2	CCC (52)
Spartalizumab Hepatocellular Carcinoma	SOLTI Breast Cancer Research Group	P2	CCC (52)
TRASTUZUMAB Hepatocellular Carcinoma	Fate Therapeutics	P2	CCC (52)
Allostim® Hepatocellular Carcinoma	Mirror Biologics, Inc.	P2/3	CCC (52)
FAPI74 Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (51)
Immunoglobulin G1, anti-(human interleukin 27) (human monoclonal SRF388 ?1-chain), disulfide with human monoclonal SRF388 ?-chain, dimer Hepatocellular Carcinoma	Coherus Oncology, Inc.	P2	CCC (51)
Pembrolizumab/Vibostolimab Coformulation Hepatocellular Carcinoma	Merck Sharp & Dohme LLC	P2	CCC (51)
Idarubicin Hydrochloride For Hepatocellular Carcinoma	Zhongda Hospital	P2/3	CCC (50)
IMMUNOGLOBULIN G1 (251-GLUTAMINE,298-ALANINE,429-LEUCINE), ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN-MUS MUSCULUS MONOCLONAL F520 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL F520 .KAPPA.-CHAIN, DIMER Hepatocellular Carcinoma	Shandong New Time Pharmaceutical Co., LTD	P2/3	CCC (50)
Namenda Hepatocellular Carcinoma	Inova Health Care Services	P2/3	CCC (50)
IMA970A Hepatocellular Carcinoma	National Cancer Institute, Naples	P1/2	CCC (49)
1.0% ip-001 for Hepatocellular Carcinoma	Robert C. Martin	P2	CCC (48)
Adbelimumab Hepatocellular Carcinoma	Fujian Cancer Hospital	P2	CCC (48)
Atilizumab Hepatocellular Carcinoma	Abbisko Therapeutics Co, Ltd	P2	CCC (48)
Atirizumab Hepatocellular Carcinoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	P2	CCC (48)
Autologous Dendritic Cell/Tumor Antigen, Adcta Hepatocellular Carcinoma	Chang Gung Memorial Hospital	P2	CCC (48)
Avatrombopag Hepatocellular Carcinoma	Second Affiliated Hospital of Guangzhou Medical University	P2	CCC (48)
Candonilimab Hepatocellular Carcinoma	Shi Ming	P2	CCC (48)
Casdozokitug Hepatocellular Carcinoma	Coherus Oncology, Inc.	P2	CCC (48)
Domvanalimab Hepatocellular Carcinoma	University of Texas Southwestern Medical Center	P2	CCC (48)

Showing 101 to 125 of 250 assets

PreviousPage 5 of 10Next